Dr. Fenton LeBon, MD
CEO, Molecular World Health
Dr. Fenton LeBon is an internationally recognized psychiatrist, innovator, and entrepreneur whose collaborative, groundbreaking work with Dr. Richard Mestayer on the therapeutic applications of Nicotinamide adenine dinucleotide (NAD) has redefined protocols in addiction treatment, regenerative medicine, and wellness. As the Co-Founder and CEO of Molecular World Health, Dr. LeBon has spearheaded advancements in the use of NAD to address critical health challenges, ranging from substance dependency and cellular repair to skin aging and overall vitality.
Dr. LeBon’s career spans decades of innovation in medicine. Prior to co-founding Molecular World Health, Fenton spent his career in traditional psychiatric and alternative medical practice, building and developing outpatient programs both the private and public sector in Georgia, Florida and Argentina.
Dr. LeBon has been instrumental in integrating NAD-based therapies into clinical practice. His work in addiction treatment has revolutionized detoxification protocols by reducing withdrawal symptoms and accelerating recovery times. In regenerative medicine, he has applied NAD to improve outcomes in physical rehabilitation, tissue repair, and skin rejuvenation, demonstrating its potential to reverse cellular aging and enhance wellness.
Under his leadership, Molecular World Health has formed collaborative strategic partnerships with other specialist and product innovators, most notably Dr. Sheila Alizadeh, PharmD and Shady Grove Pharmacy in Maryland, to develop a range of innovative NAD therapies, thus earning accolades for their evidence-based approach and transformative impact on patient care. Dr. LeBon is also a sought-after speaker at global medical and wellness conferences, where he advocates for the integration of NAD into mainstream healthcare.